Research thwarted by unreliable antibodies

More than 100 scientists met in California to find a solution to the increasingly research-thwarting problem of unreliable antibodies, according to NPR.

Researchers are finding that custom antibodies, which should help scientists zero in on specific aggressors and help fight disease. But the antibodies aren’t being as specific as they were designed to be—in fact, some of them have become so unreliable as to discredit their research.

Sometimes, the antibodies will latch onto an unintended bullseye. The result could be a confused scientist—or a ruined experiment, in one famous study cited by NPR. The problem can be worse when smaller labs make cheaper antibodies, which can be even less reliable.

At this meeting in California earlier this week, the group of assembled scientists decided on a set of voluntary standards to make antibodies easier to compare.

But that would take a lot of time and a lot of money, says NPR. There aren’t formal regulations of antibodies by the government, and a lot of younger scientists don’t necessarily recognize the problem, according to some veteran researchers. Check out NPR to see the how the regulations could workor run into a wall. 

Caitlin Wilson,

Senior Writer

As a Senior Writer at TriMed Media Group, Caitlin covers breaking news across several facets of the healthcare industry for all of TriMed's brands.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.